SMYD2 and breast carcinoma: Within the breast cancer cell line panel, MDA MB-231 cells were distinct as they demonstrated a >5-fold increase in sensitivity to LLY-507 at 7 days compared with 3 to 4-day treatment, suggesting that proliferation of this cell line may be at least in part mediated by SMYD2-dependent epigenetic mechanisms.